Skip to main content
Equibles
VSTM logo

VSTM · Verastem, Inc. · Earnings Call Transcripts & Audio

Track VSTM — free

Use VSTM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VSTM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$7.32 -0.30 (-3.94%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Aug 6, 2026

Substantial doubt about the company's ability to continue as a going concern.

“However, given the risks associated with these potential strategic or financing opportunities, they are not deemed probable for purposes of the going concern assessment and do not alleviate the substantial doubt about our ability to continue as a going concern. There can be no assurance that we will be able to generate sufficient net product revenues or obtain additional capital on favorable terms or at all.”
View the 10-Q filed Aug 6, 2026
Market Cap
$662.92M
Shares
90.56M

Verastem, Inc. Earnings Call Transcripts

Quarterly earnings calls for Verastem, Inc. (VSTM), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲198.9% $3.62M −$38.77M '19 Q4 20-02-28 ▲202.6% $5.06M −$37.99M '20 Q1 20-04-27 ▼78.6% $2.14M −$25.93M '25 Q2 25-08-07 · $11.24M −$98.52M '25 Q3 25-11-04 · $18.67M −$36.59M '26 Q1 26-05-07 LATEST ▲1775.4% $40.08M −$34.67M '26 Q2 26-08-06
Earnings call
FY26 · Q2
2026-08-06
Verastem, Inc. (VSTM) Q2 2026 Earnings Call Transcript
Confident tone VS7375 KRAS G12D inhibitor development Pipeline and registration-directed studies Earlier line of therapy and physician adoption trends
Revenue
$40.08M
▲ 1775.4% YoY
Diluted EPS
$-0.35
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-23
Verastem, Inc. (VSTM) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-03
Verastem, Inc. (VSTM) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-07
Verastem, Inc. (VSTM) Q1 2026 Earnings Call Transcript
Positive tone VS-7375 KRAS G12D pipeline Registration-directed Phase II trials AVMAPKI FAKZYNJA CO-PACK launch performance
Revenue
$18.67M
Diluted EPS
$-0.46
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-04
Verastem, Inc. (VSTM) Q4 2025 Earnings Call Transcript
Positive tone Pancreatic Cancer (RAMP 205) VS-7375 KRAS G12D Program LGSOC Commercial Launch
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Verastem, Inc. (VSTM) Q3 2025 Earnings Call Transcript
Confident tone VS-7375 KRAS G12D on/off inhibitor program Commercial launch execution and physician engagement Reimbursement and patient access
Revenue
$11.24M
Diluted EPS
$-1.35
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Verastem, Inc. (VSTM) Q2 2025 Earnings Call Transcript
Confident tone AVMAPKI FAKZYNJA CO-PACK launch Commercial execution and sales force KRAS-mutated recurrent LGSOC
Revenue
$2.14M
▼ 78.6% YoY
Diluted EPS
$-0.62
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-01-13
Verastem, Inc. (VSTM) Q4 2024 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q1
2020-04-27
Verastem, Inc. (VSTM) Q1 2020 Earnings Call
Revenue
$5.06M
▲ 202.6% YoY
Diluted EPS
$-4.20
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-02-28
Verastem, Inc. (VSTM) Q4 2019 Earnings Call
Revenue
$3.62M
▲ 198.9% YoY
Diluted EPS
$-6.12
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–10 of 10 earnings calls
Key facts CIK 1526119 CUSIP 92337C203 13F (30d) 88 filings 88 filers Visit website Investor relations